Latest Guidelines on Treatment of Gout
Acute Gout Flare Management
For acute gout attacks, use NSAIDs, colchicine, or corticosteroids as first-line therapy, with no evidence that indomethacin is superior to other NSAIDs. 1
Anti-inflammatory Drug Selection
NSAIDs: Any NSAID is acceptable (naproxen, ibuprofen, indomethacin); no single agent demonstrates superior efficacy 1
Colchicine: Use low-dose regimen (1.2 mg followed by 0.6 mg one hour later) rather than high-dose protocols 1
Corticosteroids: Oral or intra-articular administration is effective 2
- Consider in patients with contraindications to NSAIDs and colchicine 2
IL-1 blockers: Reserve for patients with frequent flares who have contraindications to all conventional agents 2
Urate-Lowering Therapy (ULT) Initiation
Allopurinol is the strongly recommended first-line urate-lowering agent for all patients with gout, including those with CKD stage ≥3. 1, 3
Indications for Starting ULT
- Recurrent gout: ≥2 attacks per year 1
- Tophaceous deposits 2
- Chronic kidney disease (moderate to severe) 4
- Urolithiasis 1
Do NOT initiate long-term ULT after a first gout attack or in patients with infrequent attacks (<2 per year). 1
Timing of ULT Initiation
When ULT is indicated during an active flare, start therapy during the flare rather than waiting for resolution, provided anti-inflammatory prophylaxis is given. 1, 3
- This represents a paradigm shift from older teaching that required waiting for flare resolution 3
- Patients are highly motivated during symptomatic periods, improving adherence 1
Allopurinol Dosing Strategy
Start allopurinol at ≤100 mg/day in patients with normal renal function, or ≤50 mg/day in CKD stage ≥3, then titrate upward to achieve target serum urate. 1, 3
Titration Protocol
- Increase by 100 mg increments weekly until target is reached 3
- Maximum FDA-approved dose: 800 mg/day 3
- Target serum urate: <6 mg/dL (or <5 mg/dL if tophi present) 2, 5
Common Pitfall to Avoid
Never start allopurinol at 300 mg/day without titration—this fixed-dose approach fails to achieve target urate in most patients and increases risk of allopurinol hypersensitivity syndrome (AHS) and flares 3
- Most patients require doses >300 mg/day to reach target 1, 3
- Low starting doses markedly reduce AHS risk 3
Allopurinol Use in Chronic Kidney Disease
Allopurinol is safe and effective in CKD stage ≥3 when initiated at low doses and titrated appropriately. 1, 3
- Start at ≤50 mg/day in CKD stage ≥3 1, 3
- Dose escalation above 300 mg/day can be performed safely to achieve urate targets 1, 3
- Xanthine oxidase inhibitors (allopurinol or febuxostat) are strongly preferred over probenecid in CKD stage ≥3 1
Febuxostat: Second-Line Agent Only
Febuxostat should NOT be used as first-line therapy; reserve it for allopurinol intolerance or failure to achieve target urate at maximum allopurinol dose. 1, 3
Specific Indications for Febuxostat
- Documented allopurinol hypersensitivity syndrome or severe cutaneous adverse reactions 3
- Failure to achieve serum urate <6 mg/dL after titrating allopurinol to 800 mg/day 3
Febuxostat Dosing
- Start at ≤40 mg/day 1, 3
- Titrate upward as needed 1
- Allopurinol and febuxostat (40 mg/day vs. 300 mg/day) show equivalent urate-lowering efficacy, but febuxostat is substantially more expensive 1, 3
Mandatory Anti-Inflammatory Prophylaxis with ULT
Strongly recommend initiating concomitant anti-inflammatory prophylaxis when starting any ULT, regardless of whether a flare is present. 1, 3
Prophylaxis Options
- Colchicine: 0.6 mg once or twice daily 3, 2
- Low-dose NSAIDs 1, 2
- Prednisone/prednisolone: 5–10 mg daily 3
Duration of Prophylaxis
Continue prophylaxis for a minimum of 3–6 months, with extension if flares persist beyond this period. 1, 3
- Shorter durations (<3 months) are associated with higher flare rates upon cessation 1
- Meta-analysis confirms gout flares are common (29.7%) in the three months immediately after stopping prophylaxis, then return to baseline levels 6
- Patients should be counseled about this rebound risk and have a plan for managing flares after prophylaxis discontinuation 6
Critical Pitfall
Omitting anti-inflammatory prophylaxis significantly increases early treatment discontinuation rates and flare frequency. 3
Practical Algorithm for Initiating ULT During an Active Flare
Treat the acute flare with full-dose anti-inflammatory therapy (e.g., indomethacin 50 mg TID, colchicine 1.2 mg then 0.6 mg 1 hour later, or prednisone 30–40 mg daily) 3
Start allopurinol simultaneously at 100 mg daily (or 50 mg daily if CKD ≥3) 3
Add prophylactic anti-inflammatory therapy (colchicine 0.6 mg daily or BID, low-dose NSAID, or prednisone 5–10 mg daily) 3
Titrate allopurinol by 100 mg increments weekly until serum urate <6 mg/dL is achieved 3
Maintain prophylaxis for at least 3–6 months 3
Additional Management Considerations
Lifestyle and Comorbidity Screening
- Screen for and manage cardiovascular risk factors, renal function, and metabolic comorbidities 2, 5
- Provide education on diet, weight management, and alcohol reduction 2
Pegloticase
Strongly recommend against pegloticase as first-line therapy. 1
- Reserve for refractory gout unresponsive to maximum doses of xanthine oxidase inhibitors and uricosurics 2
- Moderate evidence supports efficacy, but cost and safety concerns preclude first-line use 1
Uricosurics (Probenecid)
- Start at 500 mg once or twice daily with dose titration 1
- Contraindicated in CKD stage ≥3 (xanthine oxidase inhibitors strongly preferred) 1
- Consider combining with a xanthine oxidase inhibitor if target urate is not achieved with monotherapy 2
Key Pitfalls Summary
- Starting febuxostat first-line contradicts guidelines and incurs unnecessary cost 3
- Using fixed 300 mg allopurinol without titration fails to achieve target urate in most patients 3
- Initiating allopurinol at high doses increases flare risk and AHS 3
- Declaring allopurinol failure before titrating to 800 mg/day leads to premature switching 3
- Omitting flare prophylaxis significantly raises discontinuation rates 3
- Stopping prophylaxis abruptly without counseling about rebound flare risk 6